MedPharm’s CSO and University of Reading Professor co-author new book on dermal formulation development
Provides a guide on all aspects of the subject with much of the information based on the systems, processes and expertise built up at MedPharm.
MedPharm’s Chief Scientific Officer and Co-Founder, Professor Marc Brown and University of Reading’s Professor Adrian Williams have co-authored the new book: The Art and Science of Dermal Formulation Development. It is the latest addition to ‘Drugs and the Pharmaceutical Sciences’, a series of textbooks and monographs published by CRC Press.
The Art and Science of Dermal Formulation Development provides a comprehensive guide to all aspects of the subject, from the structure of skin and formulation development and performance testing to the chemical, physical and technological modulation of delivery and manufacturing processes.
Professor Brown said: “The book covers early-stage preformulation and formulation development right through to product manufacture. Much of the information is based on the systems, processes and expertise we have built up at MedPharm over the years and which have successfully led to the commercial launch of over 50 products by our clients.
The global pharmaceutical dermatology market was valued at $52 billion in 2018 and has been predicted to double over the next 10 years. Patients and consumers of OTC products globally are demanding higher standards of treatment from products which are easy to use and which help compliance.
Prof. Brown continued: “The demand within the pharmaceutical industry for these specialised and complex development services continues to grow as more becomes known about the important biochemical process occurring in the skin. This shift within the industry has been reflected in the expanding demand for MedPharm’s services.”
Prior to co-founding MedPharm in 1999 and throughout his time at the company, Professor Brown has held full, part-time or visiting academic positions at several UK universities. Both Professors have co-authored over 300 research and technical publications and supervised over 100 graduate students in the field.
Dr Jon Lenn, MedPharm CTO added “The book provides an in-depth and coherent introduction to the discipline of topical and transdermal product development for the scientific community.
He continued: “We are very pleased to be able to promote the science behind what we do. Innovating and ensuring we continue to develop our scientific expertise has been crucial and will remain fundamental to MedPharm’s future growth and support for its customers.”
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance